Skip to main content
. Author manuscript; available in PMC: 2023 Dec 1.
Published in final edited form as: Gastroenterology. 2022 Aug 7;163(6):1593–1612. doi: 10.1053/j.gastro.2022.07.076

Figure 7: Combination MEK, STAT3, and PD-1 inhibition demonstrates efficacy in a metastatic PDAC patient with chemotherapy-refractory disease, laying groundwork for clinical trial.

Figure 7:

(A) Treatment timeline for patient with chemotherapy refractory PDAC prior to initiation of Trametinib, Ruxolitinib, and Nivolumab treatment. Pre-treatment (B) and post-treatment (C) PET/CT scan showing a significant reduction in size and FDG avidity of both locally recurrent tumor in pancreatic bed (white arrows) and in a segment VII liver metastasis (yellow arrows) on PET/CT imaging following 3 months of treatment with Trametinib, Ruxolitinib, and Nivolumab; (D) Design of Phase 1 clinical trial investigating Trametinib (MEKi), Ruxolitinib (STAT3i), and Retifanlimab (αPD-1) in advanced/metastatic pancreatic cancer patients. Proposed treatment schedules, as well as scheme for biopsies/blood collection for correlative endpoints, are shown.